Humana Inc (HUM) Issues FY14 Earnings Guidance
Humana Inc (NYSE:HUM) updated its FY14 earnings guidance on Thursday. The company provided EPS guidance of $7.25-7.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.75, AnalystRatingsNetwork reports.
A number of research firms have recently commented on HUM. Analysts at Raymond James reiterated an outperform rating on shares of Humana in a research note on Thursday, August 7th. They now have a $128.00 price target on the stock, up previously from $123.00. On a related note, analysts at Leerink Swann raised their price target on shares of Humana to $140.00 in a research note on Friday, August 1st. Finally, analysts at Zacks reiterated a neutral rating on shares of Humana in a research note on Thursday, July 31st. They now have a $126.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $126.00.
Shares of Humana Inc (NYSE:HUM) opened at 123.15 on Thursday. Humana Inc has a 1-year low of $90.19 and a 1-year high of $134.93. The stock’s 50-day moving average is $125.1 and its 200-day moving average is $117.0. The company has a market cap of $18.996 billion and a price-to-earnings ratio of 18.46.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $2.19 earnings per share for the quarter, meeting the analysts’ consensus estimate of $2.19. During the same quarter last year, the company posted $2.63 earnings per share. Analysts expect that Humana Inc will post $7.73 EPS for the current fiscal year.
Humana Inc (NYSE:HUM) is a health care company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.